Analysts forecast that Paratek Pharmaceuticals Inc (NASDAQ:PRTK) will post sales of $4.87 million for the current quarter, Zacks reports. Nine analysts have provided estimates for Paratek Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $14.50 million. Paratek Pharmaceuticals reported sales of $50,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 9,640%. The company is expected to issue its next quarterly earnings results on Tuesday, November 5th.
On average, analysts expect that Paratek Pharmaceuticals will report full-year sales of $19.17 million for the current year, with estimates ranging from $12.11 million to $63.31 million. For the next fiscal year, analysts forecast that the business will post sales of $53.32 million, with estimates ranging from $22.58 million to $131.38 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. Paratek Pharmaceuticals had a negative return on equity of 459.96% and a negative net margin of 597.22%. The business had revenue of $2.05 million for the quarter, compared to the consensus estimate of $1.86 million.
PRTK has been the topic of a number of recent research reports. Zacks Investment Research raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating and set a $4.75 price objective on the stock in a research report on Friday, August 9th. HC Wainwright set a $27.00 price objective on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, September 9th. Finally, ValuEngine raised Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. Paratek Pharmaceuticals has an average rating of “Buy” and an average target price of $18.79.
Hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SA bought a new stake in Paratek Pharmaceuticals during the first quarter valued at about $36,000. Bank of Montreal Can raised its stake in Paratek Pharmaceuticals by 503.1% in the second quarter. Bank of Montreal Can now owns 7,816 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 6,520 shares during the last quarter. Alambic Investment Management L.P. purchased a new stake in Paratek Pharmaceuticals in the second quarter valued at about $82,000. Bank of America Corp DE raised its stake in Paratek Pharmaceuticals by 43.1% in the fourth quarter. Bank of America Corp DE now owns 23,504 shares of the specialty pharmaceutical company’s stock valued at $120,000 after buying an additional 7,074 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new stake in Paratek Pharmaceuticals in the second quarter valued at about $121,000. 71.26% of the stock is currently owned by institutional investors.
PRTK stock traded up $0.05 during trading on Thursday, reaching $4.45. 439,943 shares of the company traded hands, compared to its average volume of 495,875. Paratek Pharmaceuticals has a 12 month low of $2.87 and a 12 month high of $12.20. The business has a 50 day simple moving average of $4.13 and a 200 day simple moving average of $4.59. The company has a market capitalization of $143.15 million, a price-to-earnings ratio of -1.25 and a beta of 1.74. The company has a debt-to-equity ratio of 14.48, a quick ratio of 11.83 and a current ratio of 12.17.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
See Also: What is a put option?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.